Immunogenicity and tolerability of hepatitis a vaccine in HIV-infected children by Gouvêa, Aida de Fátima Thomé Barbosa et al.
544 • CID 2005:41 (15 August) • HIV/AIDS
H I V / A I D S B R I E F R E P O R T
Immunogenicity and Tolerability
of Hepatitis A Vaccine in HIV-Infected
Children
A. F. T. B. Gouvea, M. I. De Moraes-Pinto, E. Ono, M. I. S. Dinelli,
D. M. Machado, L. Y. Weckx, and R. C. M. Succi
Division of Pediatric Infectious Diseases, Federal University of Sa˜o Paulo,
Sa˜o Paulo, Brazil
The immunogenicity and tolerability of hepatitis A virus vac-
cine was evaluated in a group of 32 children with human
immunodeficiency virus (HIV) infection and 27 children
with seroreversion. After 2 doses of vaccine, 100% of children
experienced seroconversion with good toleration of the vac-
cine. There were no differences in variation of virus load
between immunized HIV-positive children and a group of
31 nonimmunized HIV-positive children with similar
characteristics.
The use of HAART has altered the natural history of AIDS,
increasing the survival and the quality of life of HIV-infected
patients [1, 2]. In parallel, one can observe the emergence of
liver disease as one of the major causes of death in HIV-infected
patients [3, 4].
Today, many HIV-infected patients have biochemical evi-
dence of liver disease [3], sometimes with a fatal outcome [5].
The full extent and causes of liver disease in children with AIDS
are unknown, but such causes include injury from drug therapy
and nonspecific abnormalities that occur in patients with
chronic illness, neoplasm, and opportunistic infection [4, 5].
In 1998, a seroepidemiologic study estimated the prevalence
of hepatitis A virus (HAV) infection as 66.6% in the general
population in the city of Sa˜o Paulo, Brazil, with prevalences of
12.1% in those aged 2–4 years, 28.1% in those aged 5–7 years,
and 35.8% in those aged 10–14 years [6].
Although hepatitis A vaccine is recommended for children
living in regions with elevated rates of hepatitis A [7], no data
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on immune response to and tolerability of the vaccine in HIV-
infected children have been available until now. The existence
of a large population of HAV-seronegative children at risk of
infection in the city of Sa˜o Paulo prompted us to assess the
immunogenicity and tolerability of hepatitis A vaccine in HIV-
infected children.
Patients and methods. This study was approved by the
ethics committee of the Federal University of Sa˜o Paulo, Brazil
(UNIFESP). Before enrolment, written informed consent was
obtained from parents or guardians. Between March 2002 and
September 2003, 32 HIV-infected children (mean age, 5.5 years)
and 27 seroreverted children (mean age, 5.1 years) were vac-
cinated at the Pediatric AIDS Clinic of UNIFESP. The HIV-
infected children were classified into clinical categories as fol-
lows: category N, 18.7%; category A, 43.7%; and category B,
37.6%. They were classified into immunologic categories as
follows: category 1, 31.2%; and category 2, 68.8%. Of 32 HIV-
infected and immunized children, 29 were receiving HAART
for a mean duration of 3.5 years; 12.9% of these children were
receiving their first regime of HAART. In this group, there were
11 patients with undetectable HIV RNA levels (!400 copies/
mL).
All of the HIV-infected children were exposed by vertical
transmission. To be enrolled in the study, the children in both
groups had to be HAV-seronegative (HAV antibody titer, !20
mIU/mL) before vaccination, have no history of any previous
viral hepatitis, not be a chronic carrier of hepatitis B or C, not
have recent contact with patients with viral hepatitis, present
with normal aspartate aminotransferase and alanine amino-
transferase serum levels, and not have any acute disease at study
entry. To assess the probability of a decline in CD4+ T cell count
associated with vaccination, a control group of 31 HIV-infected,
non–HAV-vaccinated children (mean age, 5.8 years), divided
into similar clinical and immunologic categories, was included.
Two intramuscular doses of hepatitis A vaccine (Havrix;
Glaxo SmithKline Beecham) were administered with a 6-month
interval between doses. Blood samples were obtained before
and 4–8 weeks after the first and second doses. Serum samples
were stored at 80C until tested for antibody levels.
HAV antibodies were assessed with use of a competitive
ELISA kit (Adaltis). Seroconversion was defined as having oc-
curred if the HAV antibody titer was 120 mIU/mL. For HIV-
infected children, peripheral CD4+ T lymphocyte counts and
HIV load were assessed before and 4–8 weeks after the first
and second doses. T cell counts were determined by means of
flow cytometry, and HIV load was determined by means of
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Table 1. Demographic and clinical characteristics of HIV-infected children (HIV group) and children with
seroreversion (SR group) who received hepatitis A vaccination and nonvaccinated HIV-infected children (HIV
NV group).
Characteristic
HIV group
(n p 32)
SR group
(n p 27)
HIV NV group
(n p 31) P
Age, mean years (range) 5.5 (1.9–9.3) 5.1 (1.6–9.4) 5.8 (3.3–10.5) .51a
Receiving HAART, % of subjects 90.6 … 80.6 .53b
Initial HIV load, mean log copies/mL (range) 3.26 (!400–5.4) … 3.33 (!400–5.3) .76c
Initial CD4+ T cell count, mean cells/mm3 (range) 1483 (572–2717) … 1275 (405–2730) .18c
a By analysis of variance.
b By the x2 test.
c By Student’s t test.
Figure 1. Mean hepatitis A virus (HAV) antibody titers over time in HIV-positive children (HIV group) and children with seroreversion (SR group)
who received hepatitis A vaccine.
Amplicor (Roche). To measure vaccine safety and tolerability,
parents were asked to record the occurrence of local and sys-
temic symptoms.
The x2 test and Fisher’s exact test were used for categorical
variables, and the Student’s t test was used for continuous
variables. For variables measured in the course of time, analysis
of variance (ANOVA) with repeated measures was used.
Results. The demographic characteristics of children en-
rolled in the study are summarized in table 1. Twenty-seven
(87.1%) of 31 HIV-positive children and 18 (72.0%) of 25
children with seroreversion experienced seroconversion after
the first vaccine dose ( , by the x2test). After the secondPp .157
dose, 100% of children from both groups had HAV antibody
titers 120 mIU/mL.
The geometric mean HAV antibody titers did not differ be-
tween the HIV-positive group and the seroreversion group.
ANOVA with repeated measures showed that HAV antibody
titers had the same variability over time in the same way for
both groups ( ), with an increase in antibody valuesPp .122
(figure 1 and table 2).
Few vaccinated children experienced adverse events, and
most adverse events were experienced after the first dose. Six
children in the HIV-positive group and 3 in the seroreversion
group presented with systemic adverse events. Local adverse
events were seen in 2 children from the seroreversion group
and in 1 child from the HIV-positive group (table 3).
Mean HIV load did not vary in the HIV-positive vaccinated
children ( , by ANOVA) (figure 2). Four to 8 weeksPp .635
after the first vaccine dose, 2 of 11 children with undetectable
HIV loads presented with a transient detectable level of HIV
RNA (2.9 and 2.7 log copies/mL). However, HIV load im-
mediately before the second dose was undetectable again in
both children. CD4+ T cell counts varied during the study, with
a decrease in CD4+ T cell count between the sample obtained
before the first vaccine dose and that obtained after the first
dose ( , by ANOVA). No significant variation was no-Pp .016
ticed in the other time intervals of the study ( , byP 1 .20
ANOVA) (figure 3).
To better investigate the variation in CD4+ T cell count ob-
served in the HIV-positive group, another group of HIV-in-
fected children with similar characteristics was evaluated. A
similar decrease in CD4+ T cell count (in terms of both absolute
numbers and percentages) was observed in both groups during
the 7 months of the study. Of interest, mean HIV load was
also comparable between the 2 groups, and there was no var-
iation in mean HIV load during the study period (figure 4).
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Table 2. Geometic mean titers of hepatitis A virus antibody in HIV-infected
children (HIV group) and children with seroreversion (SR group) who re-
ceived hepatitis A vaccination, by blood sample collection time.
Patient group
Geometric mean titer, mIU/mL (95% CI)
Before
first dose
Before
second dose
After
second dose
HIV group 8.0 (7.0–9.1) 82.4 (50.0–135.7) 2180.2 (1226.5–3875.5)
SR group 9.1 (7.7–10.7) 62.0 (32.0–120.1) 3627.6 (2144.4–6136.5)
Table 3. Adverse events occurring after administration of hep-
atitis A vaccine in HIV-infected children (HIV group) and children
with seroreversion (SR group).
Adverse events
No. (%) of subjects
HIV group SR group
Local events: pain 1 (3.1) 2 (7.4)
Systemic events
Fever 1 (3.1) 2 (7.4)
Erythema 1a (3.1) 1a (3.7)
Fatigue 2 (6.3) …
Headache 1 (3.1) …
Vomit or diarrhea 3 (9.4) 1 (3.7)
Arthralgia 2 (6.3) …
Myalgia 3a (9.4) 1 (3.7)
NOTE. The same child may have experienced 11 adverse event.
a One episode occurred after administration of the second dose.
Figure 2. Variation in mean HIV load over time in HIV-positive children
who received hepatitis A vaccine.
Discussion. We have assessed the antibody response to hep-
atitis A vaccine in HIV-infected children. Most of these children
were receiving HAART and had CD4+ T cell levels that were
normal for their age. We have deliberately excluded those chil-
dren who had presented with severe symptoms (clinical cate-
gory C) or low CD4+ T cell levels sometime in their lives (im-
munologic category 3). The decision to exclude these children
was based on previous studies [8] and on our own experience
[9] (A. P. Prancanica, personal correspondence), which sug-
gested that children belonging to immunologic categories 2 and
3 did not respond to immunization as well as those belonging
to immunologic category 1. Lange et al. [10] have also noticed
that the nadir CD4+ cell count was positively associated with
antibody levels.
Moreover, we had already noticed that the vaccine antigen
was also a strong determinant of antibody response. In the
children we followed up, tetanus antigen proved to be the an-
tigen that provided the best antibody response, whereas measles
antigen was the antigen with the poorest response.
However, response to hepatitis A vaccine was even better.
We found no differences between the groups in terms of their
response after the first vaccine dose or after the second vaccine
dose. Moreover, geometric mean antibody values were also very
similar in the HIV-positive and seroreversion groups.
When we compared our results with findings in the literature,
we found the same antibody response to hepatitis A vaccine
administered to healthy children [11, 12]. By contrast, HIV-
infected adults responded very weakly to hepatitis A vaccine,
compared with HIV-seronegative control subjects (seroconver-
sion rate, 77% vs. 100%; geometric mean antibody titer, 636
mIU/mL vs. 1687 mIU/mL) [13]. Neilsen et al. [14] found a
similar trend in HIV-infected adults, compared with HIV-se-
ronegative individuals (seroconversion rate, 75.6% vs. 90.2%;
geometric mean antibody titer, 100.7 IU/L vs. 1086.2 IU/L).
More recently, Kemper et al. [15], in a study involving HIV-
infected adults, also showed a low seroconversion rate for all
individuals, but the seroconversion rate was even lower in those
with low CD4+ T cell counts. We do not have an explanation
for the difference in response to hepatitis A vaccine between
HIV-positive adults and children.
Of interest, we had a low incidence of adverse events, similar
to that observed by others in studies involving healthy children
[11].
Finally, we did not detect variations in mean HIV load during
the study, with only 2 transient increases after the first dose
was administered; both increases reverted to previous levels just
before the second vaccine dose was administered. However, we
did notice a decrease in CD4+ T cell count after administration
of the first dose. Others have documented a transient decrease
in CD4+ T cell counts after vaccination with other antigens [8],
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Figure 3. Variation in CD4+ T cell count over time in HIV-positive
children who received hepatitis A vaccine.
Figure 4. Variation in mean CD4+ T cell count expressed in absolute
numbers (A) and in percentage of lymphocytes (B) and of HIV load (C) in
HIV-infected children vaccinated against hepatitis A virus (HIV vaccinated)
and in nonvaccinated HIV-infected children (HIV nonvaccinated) during
the 7 months of study.
but such decreases were always associated with an increase in
HIV load and were attributed to an activation of latent HIV
infection in lymphocytes. We did not find such an association
in the children in our study.
To further investigate the decrease in CD4+ T cell count, we
have compared HIV-infected children immunized with hepa-
titis A vaccine with a group of non-vaccinated HIV-infected
children of similar age: both groups showed the same decrease
in CD4+ T cell count (expressed both as percentages and as
absolute numbers). This suggests that the observed decrease in
CD4+ T cell count was a product of the physiologic decay of
CD4+ T cells [16] but was also due to HIV infection [17].
In summary, we have shown that HIV-infected children with-
out severe symptoms or immunosuppression can respond to
hepatitis A vaccine as well as non–HIV-infected children, with
a low rate of adverse events. In view of this finding, we would
recommend that hepatitis A vaccine be administered to children
who live in areas where HAV infection is prevalent. Hepatitis
A vaccination would help to prevent a further burden to the
liver of those children and adolescents already exposed to a
variety of hepatotoxic drugs.
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